menu
    • menu
    [{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cardiol Therapeutics

    Menu

    Cardiol Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol to Advance CardiolRx into a Late-stage Trial in Recurrent Pericarditis

                            Details : CardiolRx (cannabidiol) is an oral solution that works by inhibiting activation of the NLRP3 inflammasome. It is being evaluated for recurrent pericarditis.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 22, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

                            Details : CardiolRx (pure cannabidiol solution) which is a NLRP3 inflammasome inhibitor. It is being evaluated for the treatment of recurrent pericarditis.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 17, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatm...

                            Details : CardiolRx™ (cannabidiol), is a oral solution formulation being developed for use in heart diseases. Cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis a...

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurren...

                            Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Ac...

                            Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 07, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promot...

                            Details : Study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ (Cannabidiol) inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for...

                            Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Ph...

                            Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Recurrent Pericarditis and inhibits activation of the inflammasome pathway.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute Myo...

                            Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Acute Myocarditis and inhibits activation of the inflammasome pathway.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cardiol Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx™, into Brazil, Mexico, and Canada

                            Details : The LANCER trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19.

                            Brand Name : CardiolRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth